Top Scoops

Book Reviews | Gordon Campbell | Scoop News | Wellington Scoop | Community Scoop | Search

 

Big Pharma Profits From Addiction

Big Pharma Profits From Addiction

by Martha Rosenberg
May 8, 2014

Imagine a treatment for drug addiction and alcoholism that uses no drugs, requires no trained personnel, resources or insurance and makes no money for anyone. This "people's program" is the anonymous twelve-step programs which have quietly saved millions for 79 years.

But lately, Big Pharma sees potential in all that free healing. Increasingly, it is "partnering" with rehab facilities to monetize addiction recovery, especially by facilitating dual diagnoses that require expensive pills. A patient is no longer just an alcoholic, he is an alcoholic with bipolar disease or major depressive disorder. Ka-ching.

The US's National Institute on Drug Abuse (NIDA), often working closely with Pharma, is trying to fix one of the few things in the health care system that is not broken--free, anonymous treatment for alcoholics and addicts. Proof that NIDA has high-tech, expensive plans for addicts is apparent in its recent NIDA flier which trumpets that, "All addictions can be eliminated if the brain’s receptors can be controlled." What?

Behind the search for bio-control brain solutions like a vaccine or pill to treat addictions is Nora Volkow, NIDA director. She is called "an early champion of the idea that drug addiction is a medical problem, rather than a lack of willpower or moral fiber" which actually was the founding precept of Alcoholics Anonymous in 1935. Hello?

But unlike AA founders who discovered that free, anonymous moral support--without drugs and outside of traditional medicine--worked in almost all cases, Volkow seeks high-tech interventions which will help Pharma at the same time they harm animals.

"We have identified many of the biological and environmental factors [of addiction] and are beginning to search for the genetic variations that contribute to the development and progression of the disease," says Volkow with chilling, Orwellian fervor.

Why is seeking genetic causes and bio treatments Orwellian? First, because addiction and alcoholism are diseases of denial and few would take a medical treatment voluntarily which is why the drug Antabuse (which makes people violently sick it they drink) never caught on. If an addict were "out of denial" enough to seek a vaccine or Antabuse, he wouldn't need either. On the other hand, if he really needed it, he would be in too much denial to take it. You would think NIDA as the government's top drug agency would know that.

Secondly, Pharma, with whom Volkow has published many papers, loves to market "early treatment" drugs for diseases that have not appeared yet, treating the "risk" of heart disease, diabetes, bone thinning and mental illnesses. Patients never know if they needed the meds, are afraid to quit and Pharma creates lifelong customers. Already NIDA is talking about people "at risk" of addiction. Watch out.

Finally, development of biotech addiction treatments subjects animals to painful, unnecessary experiments when they do not even share the human afflictions. Making animals "addicts" to treat the uniquely human phenomenon is a fool's errand and a cruel one at that. One paper co-written by Volkow shows a bloody "pregnant bonnet macaque in transverse position within HR+ PET scanner... positioned so that maternal and fetal organs were within same field of view." The paper concludes that when primates are dosed with cocaine, fetuses are affected too. Animals died for this "insight"?

Animal lovers and substance counselors are not the only ones to object to NIDA's pricey, cruel nostrums. So many scientists have objected to NIDA's "vaccine for addiction," Volkow had to defend the work by denying that "funding in other areas is being sacrificed to support the medication development portfolio.”

A high-tech treatment that few will take voluntarily that treats a condition treatable with a cup of coffee and peer support and kills animals in the process? Sounds like the NISA is thinking a lot like Big Pharma.

ENDS

© Scoop Media

 
 
 
Top Scoops Headlines

 

Gordon Campbell: On The Harry/Meghan Affair, And Iran

Those “Meghzit” headlines seem apt, given how closely Britain’s January 31 exit from the European Union resembles the imminent departure from the Royal Family’s top team of Prince Harry and Meghan Markle. For young Iranians, the accidental downing of the Ukrainian airliner is just the latest example of the deadly incompetence and dishonesty of their leaders... More>>

Gordon Campbell: On The Iran Aftermath

So, evidently, you can get away with murder. It looks as though a further escalation in the ongoing war between Iran and the US has been avoided – mainly thanks to Iran NOT responding in kind to the recklessly unhinged behaviour by the United States. Given the massive outpouring of public grief in Iran over the murder of Qassem Soleimani, some reciprocal action by Iran was necessary, but (so far) it has been almost entirely symbolic in nature... More>>

Gordon Campbell: On The Aussie Bush Fires And Suleimani

In popular culture, Australia is often portrayed as Western civilisation’s last unspoiled frontier, or as its final refuge from planetary disaster. In Nevil Shute’s best-selling 1950s novel On The Beach for instance, Melbourne served as the backdrop ... More>>


Gordon Campbell: On The Best Music Of 2019

This was a year where so many of the highlights came from female musicians. But amid all that richness, there was one standout album... More>>


Gordon Campbell: On Scotland’s Renewed Independence Battle

Brexit has always been very much an English obsession... So while it isn’t surprising that Boris Johnson won the election, he might also have lost the United Kingdom in the process. More>>

Analysis: Dotcom Appeal For Surveillance Data Dismissed

Kim Dotcom’s Appeal against the decision allowing the GSCB to withold information as to communications illegally intercepted by them has been dismissed by the Court of Appeal of New Zealand. More>>

ALSO:

 
 
 
 
 


 
 
 
  • PublicAddress
  • Pundit
  • Kiwiblog